ArrowMark Colorado Holdings LLC Sells 4,071 Shares of STERIS plc $STE

ArrowMark Colorado Holdings LLC trimmed its position in STERIS plc (NYSE:STE) by 1.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 305,295 shares of the medical equipment provider’s stock after selling 4,071 shares during the quarter. STERIS comprises approximately 1.4% of ArrowMark Colorado Holdings LLC’s holdings, making the stock its 15th biggest position. ArrowMark Colorado Holdings LLC owned about 0.31% of STERIS worth $75,542,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Magnolia Capital Advisors LLC boosted its position in shares of STERIS by 1.2% in the third quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock worth $888,000 after purchasing an additional 41 shares during the period. Colonial Trust Co SC raised its position in shares of STERIS by 0.3% during the 3rd quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock valued at $3,051,000 after purchasing an additional 42 shares during the period. Allworth Financial LP raised its position in shares of STERIS by 7.3% during the 2nd quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 45 shares during the period. Geneos Wealth Management Inc. lifted its stake in shares of STERIS by 34.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 45 shares in the last quarter. Finally, Fifth Third Bancorp lifted its stake in shares of STERIS by 1.6% during the 3rd quarter. Fifth Third Bancorp now owns 2,953 shares of the medical equipment provider’s stock valued at $731,000 after buying an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on STE shares. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Price Performance

STE stock opened at $214.66 on Friday. STERIS plc has a one year low of $204.90 and a one year high of $269.44. The company’s fifty day moving average price is $250.96 and its 200-day moving average price is $250.51. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The company has a market capitalization of $21.05 billion, a PE ratio of 29.94 and a beta of 1.05.

STERIS (NYSE:STE) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Tuesday, February 17th will be given a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s dividend payout ratio (DPR) is presently 35.15%.

Insider Activity

In other news, Director Cynthia L. Feldmann sold 3,098 shares of STERIS stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the sale, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.07% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.